… in castration-resistant prostate cancer (CRPC), our findings argued that Plk1 activation was
… Plk1 inhibitors in combination drug trials to enhance the efficacy of ASIs in CRPC. Cancer …

… in the development of Plk1 inhibitors for cancer management. Plk1 inhibition has been shown
to … was shown to enhance the antineoplastic activity of metformin in prostate cancer (52). …

… prostate cancer. Herein, we show that a combination of Plk1 inhibitor GSK461364A and
BRD4 inhibitor JQ1 had a strong synergistic effect on castration-resistant prostate cancer (CRPC…

… Plk1 and DDR signaling pathways in prostate cancer, we sought to investigate whether Plk1
inhibitors … of genotoxic stress, in combination with inhibition of AR signaling, could be used …

… Herein, by combination with Plk1 inhibitor BI2536, we show a robust sensitization of
olaparib in 22RV1, a BRCA1-deficient CRPC cell line, as well as in CRPC xenograft tumors. …

… In this study, we assess the effects of Plk1 … of Plk1 correlated with tumorigenicity and that
inhibition of Plk1 caused reduction of AR expression and AR activity. Furthermore, Plk1 inhibitor …

… and apoptosis induced by genistein in human cancer cells. In addition, genistein has … in
prostate cancer. We hypothesized that the Plk1 inhibitor genistein would be effective in cancers …

… and partial reversal of cell death by a necroptosis inhibitor. Our studies suggest that LNCaP-AI
… to Plk1 inhibition that induces necroptosis. Harnessing necroptosis through Plk1 inhibition …

14547 Background: BI 2536 is a novel, highly selective, potent inhibitor of Polo-like kinase 1
(Plk1), a key regulator of mitotic progression. BI 2536 has demonstrated favorable …

… that BI2536, a specific Plk1 inhibitor, acted synergistically with metformin in inhibiting PCa
cell proliferation. Furthermore, we also provide evidence that Plk1 inhibition makes PCa cells …